Seoul Pharma Co. Ltd Working Capital to Net Assets Ratio
Seoul Pharma Co. Ltd working capital to net assets ratio. Seoul Pharma Co. Ltd (018680) has a Working Capital to Net Assets ratio of 46.7% as of September 2025. Working capital of ₩19.30 Billion (current assets of ₩35.76 Billion minus current liabilities of ₩16.46 Billion) is measured against net assets of ₩41.30 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check tangible net worth ratio of Seoul Pharma Co. Ltd to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Seoul Pharma Co. Ltd (2012–2024)
Working capital to net assets ratio of Seoul Pharma Co. Ltd from 2012 to 2024. This chart shows how Seoul Pharma Co. Ltd's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2012 to 2024. As of September 2025, the ratio stands at 46.7%, reflecting working capital of ₩19.30 Billion against net assets of ₩41.30 Billion KRW. See Seoul Pharma Co. Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Seoul Pharma Co. Ltd Working Capital to Net Assets Ratio by Year (2012–2024)
Seoul Pharma Co. Ltd working capital to net assets ratio by year from 2012 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for Seoul Pharma Co. Ltd from 2012 to 2024, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Seoul Pharma Co. Ltd assets under control.
| Year | WC/NA Ratio | Working Capital (KRW) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 45.1% | ₩18.12 Billion | ₩40.17 Billion | ₩32.26 Billion | ₩14.14 Billion | ▲ +31.9 pp |
| 2023 | 13.2% | ₩5.08 Billion | ₩38.56 Billion | ₩25.61 Billion | ₩20.53 Billion | ▼ -21.1 pp |
| 2022 | 34.2% | ₩12.12 Billion | ₩35.42 Billion | ₩26.01 Billion | ₩13.89 Billion | ▲ +55.3 pp |
| 2021 | -21.1% | ₩-3.99 Billion | ₩18.96 Billion | ₩24.81 Billion | ₩28.80 Billion | ▼ -47.0 pp |
| 2020 | 25.9% | ₩7.49 Billion | ₩28.85 Billion | ₩25.93 Billion | ₩18.45 Billion | ▲ +31.3 pp |
| 2019 | -5.3% | ₩-1.51 Billion | ₩28.45 Billion | ₩25.22 Billion | ₩26.73 Billion | ▼ -65.1 pp |
| 2018 | 59.8% | ₩30.09 Billion | ₩50.31 Billion | ₩44.11 Billion | ₩14.02 Billion | ▲ +18.8 pp |
| 2017 | 41.0% | ₩22.07 Billion | ₩53.86 Billion | ₩40.51 Billion | ₩18.44 Billion | ▼ -19.5 pp |
| 2016 | 60.4% | ₩25.43 Billion | ₩42.07 Billion | ₩37.38 Billion | ₩11.95 Billion | ▲ +42.1 pp |
| 2015 | 18.3% | ₩6.14 Billion | ₩33.53 Billion | ₩30.02 Billion | ₩23.88 Billion | ▲ +10.7 pp |
| 2014 | 7.6% | ₩2.38 Billion | ₩31.10 Billion | ₩24.78 Billion | ₩22.40 Billion | ▼ -3.7 pp |
| 2013 | 11.3% | ₩3.66 Billion | ₩32.25 Billion | ₩19.97 Billion | ₩16.31 Billion | ▼ -9.7 pp |
| 2012 | 21.1% | ₩5.35 Billion | ₩25.38 Billion | ₩18.73 Billion | ₩13.38 Billion | — |